Effects of orlistat, simvastatin, and orlistat + simvastatin in obese patients with hypercholesterolemia: A randomized, open-label trial

Current Therapeutic Research - Clinical and Experimental

Volumn 63, Issue 9, 2002, Pages 621-633

  Derosa, Giuseppe ^a   Mugellini, Amedeo ^a   Ciccarelli, Leonardina ^a   Rinaldi, Andrea ^a   Fogari, Roberta ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Blood pressure; Diet; Hypercholesterolemia; Obese; Orlistat; Simvastatin

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BODY COMPOSITION; BODY MASS; BODY WEIGHT; CALORIC INTAKE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DIETARY INTAKE; DISEASE SEVERITY; DOSE RESPONSE; EXERCISE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCHOLESTEROLEMIA; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; METEORISM; OBESITY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; TREATMENT PLANNING; WEIGHT REDUCTION;

EID: 0036748432     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(02)80066-2     Document Type: Article

References (51)

1. World Health Organization. Obesity: Preventing and managing the global epidemic. Report of a WHO Consultation on Obesity, Geneva, Switzerland, June 3-5, 1997. Geneva, Switzerland: WHO; 1998.
2. Wilding J. Science, medicine, and the future: Obesity treatment. BMJ. 1997;315:997-1000.
3. McIntyre AM. Burden of illness review of obesity: Are the true costs realised? J R Soc Health. 1998;118:76-84.
4. Colditz GA, Willet WC, Rotnitzky A, Mansen JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med. 1995;122:481-486.
5. Bray GA. Pathophysiology of obesity. Am J Clin Nutr. 1992;55(Suppl 2):488S-494S.
6. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: A 26-year follow-up of participants in the Framingham Heart Study. Circulation. 1983;67:968-977.
7. Hanefeld M, Fischer S, Schmechel H, et al. Diabetes Intervention Study: Multi-intervention trial in newly diagnosed NIDDM. Diabetes Care. 1991;14:308-317.
8. Chen Z, Peto R, Collins R, et al. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. BMJ. 1991;303:276-282.
9. Kannel WB. Range of serum cholesterol values in the population developing coronary artery disease. Am J Cardiol. 1995;76:69C-77C.
10. Levine GN, Keaney JF Jr, Vita JA. Cholesterol reduction in cardiovascular disease: Clinical benefits and possible mechanisms. N Engl J Med. 1995;332:512-521.
11. Shepherd J, Cobbe SM, Ford I, et al, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
12. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615-1622.
13. Hagemenas FC, Pappu AS, Illingworth DR. The effects of simvastatin on plasma lipoproteins and cholesterol homeostasis in patients with heterozygous familial hypercholesterolemia. Eur J Clin Invest. 1990;20:150-157.
14. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
15. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens. 1999;17:151-183.
16. Zhi J, Melia AT, Guerciolini R, et al. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther. 1994;56:82-85.
17. HMG-CoA reductase inhibitors for hypercholesterolemia. N Engl J Med. 1988;319:1222-1223.
18. Todd PA, Goa KL. Simvastatin: A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia. Drugs. 1990;40:583-607.
19. Betteridge DJ. Combination drug therapy for dyslipidemia. Curr Opin Lipidol. 1993;4:49-55.
20. Agheli N, Jacotot B. Effect of simvastatin and fenofibrate on the fatty acid composition of hypercholesterolaemic patients. Br J Clin Pharmacol. 1991;32:423-428.
21. Farnier M, Bonnefous F, Debbas N, Irvine A. Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia. Arch Intern Med. 1994;154:441-449.
22. Wannamethee G, Shaper AG. Weight change in middle-aged British men: Implications for health. Eur J Clin Nutr. 1990;44:133-142.
23. Singh RB, Rastogi SS, Vermi R, et al. Randomised controlled trial of cardioprotective diet in patients with recent acute myocardial infarction: Results of one year follow up. BMJ. 1992;304:1015-1019.
24. Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord. 1992;16:397-415.
25. Lean ME, Han TS, Morrison CE. Waist circumference as a measure for indicating need for weight management. BMJ. 1995;311:158-161.
26. Rexrode KM, Carey VJ, Hennekans CH, et al. Abdominal adiposity and coronary heart disease in women. JAMA. 1999;280:1843-1848.
27. Sjostrom L, Rissanen A, Andersen T, et al, for the European Multicentre Orlistat Study Group. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet. 1998;352:167-172.
28. Rossner S, Sjostrom L, Noack R, et al, for the European Orlistat Obesity Study Group. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. Obes Res. 2000;8:49-61.
29. Van Gaal L, Mertens I, Peiffer F, et al. Effect of weight loss treatment with orlistat on blood pressure and heart rate among obese patients [abstract]. Obes Res. 1999;7(Suppl 1):O205.
30. Zavoral JH. Treatment with orlistat reduces cardiovascular risk in obese patients. J Hypertens. 1998;16:2013-2017.
31. Wilson TW, Alonso-Galicia M, Roman RJ. Effects of lipid-lowering agents in the Dahl salt-sensitive rat. Hypertension. 1998;31:225-231.
32. Jiang J, Roman RJ. Lovastatin prevents development of hypertension in spontaneously hypertensive rats. Hypertension. 1997;30:968-974.
33. Dechend R, Fiebeler A, Park JK, et al. Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Circulation. 2001;104:576-581.
34. Sung BH, Izzo JL Jr, Wilson MF. Effects of cholesterol reduction on BP response to mental stress in patients with high cholesterol. Am J Hypertens. 1997;10:592-599.
35. Straznicky NE, Howes LG, Lam W, Louis WJ. Effects of pravastatin on cardiovascular reactivity to norepinephrine and angiotensin II in patients with hypercholesterolemia and systemic hypertension. Am J Cardiol. 1995;75:582-586.
36. Glorioso N, Troffa C, Filigheddu F, et al. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension. 1999;34:1281-1286.
37. Jarai Z, Kapocsi J, Farsang C, et al. Effect of fluvastatin on serum lipid levels in essential hypertension [in Hungarian]. Orv Hetil. 1996;137:1857-1859.
38. Abetel G, Poget PN, Bonnabry JP. Hypotensive effect of an inhibitor of cholesterol synthesis (fluvastatin): A pilot study [in French]. Schweiz Med Wochenschr. 1998;128:272-277.
39. Sartor G, Katzman P, Eizyk E, et al. Simvastatin treatment of hypercholesterolemia in patients with insulin dependent diabetes mellitus. Int J Clin Pharmacol Ther. 1995;33:3-6.
40. Antonicelli R, Onorato G, Pagelli P, et al. Simvastatin in the treatment of hypercholesterolemia in elderly patients. Clin Ther. 1990;12:165-171.
41. Kool M, Lustermans F, Kragten H, et al. Does lowering of cholesterol levels influence functional properties of large arteries? Eur J Clin Pharmacol. 1995;48:217-223.
42. D'Agostino RB, Kannel WB, Stepanians MN, D'Agostino LC. Efficacy and tolerability of lovastatin in hypercholesterolemia in patients with systemic hypertension. Am J Cardiol. 1993;71:82-87.
43. Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: A randomized controlled trial. JAMA. 1999;281:235-242.
44. Rossner S, Bjorvell H. Early and late effects of weight loss on lipoprotein metabolism in severe obesity. Atherosclerosis. 1987;64:125-130.
45. Plosker GL, McTavish D. Simvastatin: A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia. Drugs. 1995;50:334-363.
46. Illingworth DR, Stein EA, Knopp RH, et al. A randomized multicenter trial comparing the efficacy of simvastatin and fluvastatin. J Cardiovasc Pharmacol Ther. 1996;1:23-30.
47. Illingworth DR, Tobert JA. A review of clinical trials comparing HMG-CoA reductase inhibitors. Clin Ther. 1994;16:366-385.
48. Illingworth DR, Erkelens DW, Keller U, et al. Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastin, and simvastatin. Lancet. 1994;343:1554-1555.
49. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
50. Kjekshus J, Pedersen TR. Reducing the risk of coronary events: Evidence from the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol. 1995;76:64C-68C.
51. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet. 1995;345:1274-1275.